Bioactive Sphingolipids in Cancer Biology and Therapy
Description
This volume presents information on both the basic and clinical aspects of sphingolipid-metabolizing enzymes in various cancers. The volume also includes discussions of the innovative techniques and approaches for quantitative analysis and imaging that could significantly impact the general understanding of this topic, and the potential benefit of targeting sphingolipid enzymes to develop novel cancer therapeutics. As well, the volume includes a critical examination of the specific pathways and pathobiologies associated with the altered regulation of sphingolipid metabolism as a contributor to the development and/or maintenance of pathological conditions such as cancer.
More details
Other editions
Additional editions
Persons
Yusuf A. Hannun, MD, is Director, Stony Brook Cancer Center, Vice Dean, Cancer Medicine, and Professor, Biochemistry and Cell Biology, Stony Brook University. He is a renowned molecular biologist and physician-scientist investigating the molecular mechanisms of cancer, with an expertise in sphingolipids. Dr. Hannun is currently on the Editorial Board of several journals, including Biomedicine and Biotechnology , Frontiers in Membrane Physiology , and Biophysics, Chemistry and Physics of Lipids , and has received several honors, including the ASBMB Avanti Award in Lipids and ISI Highly Citied Researchers (in Biology and Biochemistry), and is Fellow, the American Association and Advancement of Science. He has published 448 scientific papers, which have received more than 34,100 citations.
Chiara Luberto, Ph.D., is Research Associate Professor of Physiology and Biophysics, Stony Brook University.
Cungui Mao, Ph.D., is Associate Professor of Medicine, Stony Brook University.
Lina Marie Obeid, M.D., is Professor of Medicine and Dean of Research, Stony Brook University.
Content
1 Basics of Sphingolipid Metabolism and Signaling.-2 Role of Sphingolipids in Hematological Malignancies: Lymphoproliferative disorders.-3 Role of Sphingolipids in Hematological Malignancies: Myeloproliferative Disorders.-4 Sphingolipids as Mediators of Breast Cancer Progression, Metastasis, Response, and Resistance to Chemotherapy.-5 Role of Sphingolipids in Non-Melanoma Skin Cancer.-6 Dysregulation of Sphingolipid Metabolism in Melanoma: Roles in Pigmentation, Cell Survival and Tumor Progression.-7 Colon Cancer: the Role of Sphingolipid Metabolic Enzymes.-8 Dietary Sphingolipids in Colon Cancer Prevention.-9 Role of Sphingolipids in Liver Cancer.-10 Pancreatic Cancer and Sphingolipids.-11 Sphingolipids in the Pathogenesis of Head and Neck and Lung Cancers: Translational Aspects for Therapy and Biomarker Development.-12 The Role and Function of Sphingolipids in Glioblastoma Multiforme.-13 Systems Biology Approaches for Studying Sphingolipid Signaling.-14 Qualitative and Quantitative Measurements of Sphingolipids by Mass Spectrometry.-15 Detection and Distribution of Sphingolipids in Tissue by FTICR MALDI-Imaging Mass Spectrometry.-16 Sphingoproteomics: Proteomic Strategies to Examine Sphingolipid Biology.-17 Utilization of Caged Ceramide and Ceramide 1-Phosphate Analogs for Monitoring Cellular Events after Photoactivation.-18 Chemotherapy and Sphingolipid Metabolism.-19 Chemical Probes of Sphingolipid Metabolizing Enzymes.-20 Use of Fenretinide to Increase Cytotoxic Dihydroceramides as a Novel Cancer Chemotherapeutic Approach